Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:MTFB
CUSIPN/A
Phone609-608-0032
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-773.10%
Return on Assets-183.64%
Miscellaneous
Employees8
Outstanding Shares263,130,000
Market Cap£93.75 million
Motif Bio (LON:MTFB) Frequently Asked Questions
What is Motif Bio's stock symbol?
Motif Bio trades on the London Stock Exchange (LON) under the ticker symbol "MTFB."
What price target have analysts set for MTFB?
5 Wall Street analysts have issued 12-month target prices for Motif Bio's shares. Their forecasts range from GBX 95 to GBX 116. On average, they expect Motif Bio's share price to reach GBX 107.20 in the next year. This suggests a possible upside of 257.3% from the stock's current price. View Analyst Price Targets for Motif Bio.
What is the consensus analysts' recommendation for Motif Bio?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Motif Bio in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Motif Bio.
Who are some of Motif Bio's key competitors?
Some companies that are related to Motif Bio include BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Wellness Solutions (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV), Faron Pharmaceuticals Oy (FARN), Bionomics (BNO), Fennec Pharmaceuticals (FRX), ImmunoVaccine (IMMVF), Arix Bioscience (ARIX) and Mereo BioPharma Group (MPH).
Who are Motif Bio's key executives?
Motif Bio's management team includes the folowing people:
- Mr. Graham George Lumsden, CEO & Exec. Director (Age 58)
- Mr. Jonathan E. Gold, CFO & Exec. Director (Age 45)
- Dr. David B. Huang, Chief Medical Officer (Age 43)
- Mr. Robert Dickey IV, Advisor (Age 62)
- Liam O'Donoghue, Company Sec.
How do I buy shares of Motif Bio?
Shares of MTFB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Motif Bio's stock price today?
One share of MTFB stock can currently be purchased for approximately GBX 30.
How big of a company is Motif Bio?
Motif Bio has a market capitalization of £93.75 million. Motif Bio employs 8 workers across the globe.
What is Motif Bio's official website?
How can I contact Motif Bio?
Motif Bio's mailing address is One Tudor Street, LONDON, EC4Y 0AH, United Kingdom. The company can be reached via phone at 609-608-0032.
MarketBeat Community Rating for Motif Bio (LON MTFB)
MarketBeat's community ratings are surveys of what our community members think about Motif Bio and other stocks. Vote "Outperform" if you believe MTFB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTFB will underperform the S&P 500 over the long term. You may vote once every thirty days.
